Vectura up on formulation deal with GSK

Vectura Group plc (LSE:VEC) rose 6.5p (13%) to 55p on Friday after granting GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) non-exclusive, worldwide rights to use its dry powder formulation technology for two...